(4) identified four prominent genetic subtypes in DLBCL with different responses to immunochemotherapy: MCD (the co-occurrence of MYD88L265P and CD79B mutations), BN2 (BCL6 fusions and NOTCH2 mutations), N1 (NOTCH1 mutations), and EZB (EZH2 mutations and BCL2 translocations), and uneven distributions of these four subtypes were found between the high- and low-risk groups. Here, BCL2 is linked to diffuse large B-cell lymphoma.